# OnCo record aml (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/aml/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "aml" ;
  schema:name "Acute myeloid leukaemia"@en ;
  schema:description "Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."@en ;
  schema:url <https://onco.cc/cancers/aml/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_myeloid_leukemia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q264118> ;
  schema:citation <https://ashpublications.org/blood/article/140/12/1345/485817>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411> ;
  onco:tag "heme" ;
  onco:related <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/bpdcn/>, <https://onco.cc/cancers/cmml/>, <https://onco.cc/cancers/cml/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/bh3-profiling/> ;
  onco:targets <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/idh/>, <https://onco.cc/targets/menin/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd33/>, <https://onco.cc/targets/cd123/>, <https://onco.cc/targets/cd47/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/cd70/>, <https://onco.cc/targets/npm1/>, <https://onco.cc/targets/kmt2a/> ;
  onco:drugs <https://onco.cc/drugs/decitabine/>, <https://onco.cc/drugs/idarubicin/>, <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/rasburicase/>, <https://onco.cc/drugs/histamine-dihydrochloride/>, <https://onco.cc/drugs/dorocubicel/>, <https://onco.cc/drugs/aminopterin/> ;
  onco:companies <https://onco.cc/companies/treadwell-therapeutics/>, <https://onco.cc/companies/molecular-partners/>, <https://onco.cc/companies/orca-bio/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/servier/>, <https://onco.cc/companies/syndax/>, <https://onco.cc/companies/kura-oncology/>, <https://onco.cc/companies/taiho-oncology/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/rigel-pharmaceuticals/>, <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/aml-signalling/> ;
  onco:terms <https://onco.cc/terms/eln-risk/>, <https://onco.cc/terms/flt3-itd-allelic-ratio/>, <https://onco.cc/terms/mrd-negative-cr/>, <https://onco.cc/terms/differentiation-syndrome/>, <https://onco.cc/terms/tumor-lysis-syndrome/> ;
  onco:trials <https://onco.cc/trials/aaml0531/>, <https://onco.cc/trials/nct06387069/>, <https://onco.cc/trials/nct05586074/>, <https://onco.cc/trials/nct06852222/>, <https://onco.cc/trials/nct05429632/>, <https://onco.cc/trials/nct06788756/>, <https://onco.cc/trials/nct07007312/>, <https://onco.cc/trials/nct07211958/>, <https://onco.cc/trials/nct04229979/>, <https://onco.cc/trials/nct04256317/>, <https://onco.cc/trials/nct05907057/>, <https://onco.cc/trials/nct07581002/>, <https://onco.cc/trials/nct07255872/>, <https://onco.cc/trials/nct06389292/>, <https://onco.cc/trials/nct03182244/>, <https://onco.cc/trials/apl0406/>, <https://onco.cc/trials/viale-a/> ;
  onco:people <https://onco.cc/people/hartmut-dohner/>, <https://onco.cc/people/uwe-platzbecker/>, <https://onco.cc/people/pierre-fenaux/> ;
  onco:journals <https://onco.cc/journals/blood-cancer-discovery/>, <https://onco.cc/journals/blood-cancer-journal/>, <https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/>, <https://onco.cc/journals/current-hematologic-malignancy-reports/>, <https://onco.cc/journals/haematologica/>, <https://onco.cc/journals/hematology-oncology-and-stem-cell-therapy/>, <https://onco.cc/journals/journal-of-hematology-and-oncology/>, <https://onco.cc/journals/leukemia-and-lymphoma/>, <https://onco.cc/journals/leukemia-research/> ;
  onco:pipeline <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/hmpl-306/>, <https://onco.cc/drugs/clifutinib/>, <https://onco.cc/drugs/bleximenib/>, <https://onco.cc/drugs/cusatuzumab/>, <https://onco.cc/drugs/cart84/>, <https://onco.cc/drugs/rvu120/>, <https://onco.cc/drugs/bexmarilimab/>, <https://onco.cc/drugs/ard103/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/pairings/menin-plus-venetoclax-hma/>, <https://onco.cc/trials/myelomatch/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/drugs/cpx-351/>, <https://onco.cc/technologies/bh3-profiling/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/ideas/idea-mrd-guided-transplant-aml/>, <https://onco.cc/ideas/idea-shortened-venetoclax/>, <https://onco.cc/drugs/tagraxofusp/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:standardOfCare <https://onco.cc/drugs/gemtuzumab-ozogamicin/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/terms/eln-risk/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/trials/ratify/>, <https://onco.cc/trials/quantum-first/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/gemtuzumab-ozogamicin/>, <https://onco.cc/trials/alfa-0701/>, <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/drugs/cpx-351/>, <https://onco.cc/trials/cpx-351-301/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/magrolimab/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/trials/viale-a/>, <https://onco.cc/trials/agile/>, <https://onco.cc/trials/ascertain-v/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/trials/quazar-aml-001/>, <https://onco.cc/trials/morpho/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/trials/admiral/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/olutasidenib/>, <https://onco.cc/drugs/enasidenib/>, <https://onco.cc/terms/differentiation-syndrome/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/trials/augment-101/>, <https://onco.cc/trials/komet-001/>, <https://onco.cc/pairings/menin-plus-venetoclax-hma/>, <https://onco.cc/terms/differentiation-syndrome/> .